Acura Shares Rise 17% as Company Announces Results of Meeting with FDA

Acura Pharmaceuticals (NASDAQ: ACUR ) today announced that it met on December 5th with the U.S. Food and Drug Administration (FDA) to review the results of Acura's Study AP-ADF-301 (Study 301), a phase II clinical study in 40 recreational drug abusers assessing the abuse liability of snorting a crushed